L. Roy Papp & Associates’s Indivior Pharmaceuticals INDV Stock Holding History

L. Roy Papp & Associates’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	+5,000	New	+$181K	0.02%	191

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

L. Roy Papp & Associates's INDV Position: Q2 2026 in Review

L. Roy Papp & Associates opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 5,000 shares worth $205K. The stake represents 0.02% of the portfolio and ranks #191 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

L. Roy Papp & Associates held 5,000 shares of Indivior Pharmaceuticals worth $205K as of Q2 2026.
Indivior Pharmaceuticals was a new L. Roy Papp & Associates position in Q2 2026.
Indivior Pharmaceuticals made up 0.02% of L. Roy Papp & Associates's portfolio in Q2 2026, its #191 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on L. Roy Papp & Associates's 13F filing for Q2 2026, filed 23 Jul 2026.